IDC10 Code = E70.0
Enzyme Commission Number = 1.14.16.1
Genomic coordinate ( human 12:102,386,326 PAH).
Cytoband (human 12q23.2 PAH).
Intraband %= 51.6% PAH
OMIM’ genes @ 12q23.2 = 38 genes.
ClinVar = 3,300 PAH variants reported.
Hyperbolic Umbilic Chromosome-12 is 1,200 genes.
Chromosome-12 Cytobands: WG2B2GC_CBG5B2G6 (12/29)
Here I present: “Phenylalanine Hydroxylase Deficiency”, Victor McKusick, Mendelian Inheritance in Man’, 1966. (PKU)
INTRODUCTION.
This blog post provides a comprehensive clinical and genetic breakdown of Phenylketonuria (PKU), focusing on the deficiency of the enzyme Phenylalanine Hydroxylase (PAH).
🧬 Normal vs. Pathological Metabolism
Normal State (Green): Adequate PAH activity converts Phenylalanine (Phe) efficiently into Tyrosine, maintaining stable metabolic balance.
Transition State (Yellow): Small drops in residual PAH activity lead to disproportionately large jumps in blood phenylalanine levels.
PKU State (Red): Severe PAH deficiency causes massive (Phe) accumulation, triggering metabolic instability and neurotoxicity.
🧠 Neurobiological Mechanism & Toxicity
Transporter Competition: Elevated blood (Phe) outcompetes other large neutral amino acids (tyrosine, tryptophan) for the LAT1 transporter at the blood-brain barrier.Neurotransmitter Deficits: Blocked uptake reduces brain synthesis of critical neurotransmitters, lowering dopamine, norepinephrine, and serotonin.Clinical Result: This cerebral deficiency drives the cognitive dysfunction and neurological symptoms characteristic of PKU.
📊 Clinical Spectrum & Phenotypes
The severity of the condition directly correlates with blood phenylalanine levels and residual enzyme activity:
Normal: Standard metabolic baseline.
mHPA (Mild Hyperphenylalaninemia): < 360.
Mild PKU: 360– 600.
Moderate PKU: 600 — 1200.
Classic PKU: > 1200(Near-zero PAH activity).
🛠️ Genetics & Treatment Architecture
Genetic Mapping: Located on Chromosome 12 (cytoband 12q23.2) within the PAH gene.
Variant Defects: Caused by missense mutations, regulatory domain variants, splice-site issues, or tetramerization defects.
Therapeutic Options: Controlled via strict dietary (Phe) restriction, Sapropterin for responsive variants, Pegvaliase enzyme therapy for adults, and Large Neutral Amino Acids to block LAT1 transport.
Clinical Goal: Maintain blood (Phe) levels = 360.
